We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+16.42%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.73B
AUM Growth
+$239M
Cap. Flow
+$39.4M
Cap. Flow %
2.27%
Top 10 Hldgs %
27.21%
Holding
142
New
9
Increased
33
Reduced
17
Closed
2

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$27.4M
2
JNJ icon
Johnson & Johnson
JNJ
+$20.9M
3
PCRX icon
Pacira BioSciences
PCRX
+$12.4M
4
AFAM
Almost Family Inc
AFAM
+$10.8M
5
OBSV
ObsEva SA Ordinary Shares
OBSV
+$10.3M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$27.7M
2
TSRO
TESARO, Inc.
TSRO
+$22.6M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$12.3M
4
MEDP icon
Medpace
MEDP
+$4.87M
5
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$3.11M

Sector Composition

Rank Sector Weight
1 Healthcare 82.21%
2 Financials 2.45%
3 Consumer Discretionary 0.63%
4 Industrials 0.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TBPH icon
26
Theravance Biopharma
TBPH
$877M
$22.1M 1.27%
600,000
– –
JNJ icon
27
Johnson & Johnson
JNJ
$619B
$21.8M 1.26%
+175,000
New +$20.9M
WMGI
28
DELISTED
Wright Medical Group Inc
WMGI
$20.9M 1.2%
670,000
+3,000
+0.4% +$81.4K
ACRS icon
29
Aclaris Therapeutics
ACRS
$851M
$20.1M 1.16%
675,000
-425,000
-39% -$12.3M
GILD icon
30
Gilead Sciences
GILD
$162B
$19.5M 1.12%
286,500
+10,000
+4% +$703K
LKFT
31
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.71B
$18.1M 1.04%
210,000
– –
JAZZ icon
32
Jazz Pharmaceuticals
JAZZ
$16.7B
$18M 1.04%
123,700
– –
NBIX icon
33
Neurocrine Biosciences
NBIX
$16.2B
$17.8M 1.02%
410,000
– –
PRTA icon
34
Prothena Corp
PRTA
$449M
$17.3M 1%
309,500
– –
COLL icon
35
Collegium Pharmaceutical
COLL
$944M
$17.1M 0.99%
1,700,000
+100,000
+6% +$1.49M
RARX
36
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$16.8M 0.97%
788,959
-37,041
-4% -$708K
AMGN icon
37
Amgen
AMGN
$219B
$16.1M 0.93%
98,000
+1,500
+2% +$249K
AMRN
38
Amarin Corp
AMRN
$301M
$16M 0.92%
250,060
+485
+0.2% +$30.8K
HOLX
39
DELISTED
Hologic
HOLX
$14.5M 0.83%
340,000
+75,000
+28% +$3.06M
WTW icon
40
Willis Towers Watson
WTW
$31.6B
$14.4M 0.83%
110,000
– –
CHRS icon
41
Coherus Oncology
CHRS
$194M
$14.3M 0.82%
675,000
+190,500
+39% +$4.69M
DHR icon
42
Danaher
DHR
$141B
$13.7M 0.79%
180,480
– –
EW icon
43
Edwards Lifesciences
EW
$51.5B
$13.4M 0.77%
427,500
+66,000
+18% +$2.07M
WBA
44
DELISTED
Walgreens Boots Alliance
WBA
$13.4M 0.77%
161,000
– –
NVTA
45
DELISTED
Invitae Corporation
NVTA
$13.3M 0.77%
1,200,000
– –
DERM
46
DELISTED
Dermira, Inc.
DERM
$13.2M 0.76%
387,600
+25,000
+7% +$807K
BIIB icon
47
Biogen
BIIB
$30.5B
$13.1M 0.76%
48,000
+1,000
+2% +$283K
CLVS
48
DELISTED
Clovis Oncology, Inc.
CLVS
$11.7M 0.68%
184,500
+74,500
+68% +$4.53M
TXMD icon
49
TherapeuticsMD
TXMD
$24.2M
$11.5M 0.66%
32,000
-2,400
-7% -$743K
EHC icon
50
Encompass Health
EHC
$12.4B
$11.3M 0.65%
333,105
– –
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return

Rock Springs Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, Rock Springs Capital Management held 142 positions worth $1.73B, up 16% from $1.49B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management's Q1 2017 filing shows 9 new, 33 increased, 17 reduced and 2 closed positions. Its largest new stake was Humana: 132,500 shares worth $27.3M. The largest sale was Aetna Inc, an estimated $27.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 81% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q1 2017 buy was Humana: 132,500 shares worth $27.3M.
  • Rock Springs Capital Management added most to Pacira BioSciences in Q1 2017, an estimated $12.4M increase.
  • Rock Springs Capital Management's biggest Q1 2017 reduction was Aetna Inc, cutting an estimated $27.7M.
  • Rock Springs Capital Management fully exited Medpace in Q1 2017, selling an estimated $4.87M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $1.73B portfolio in Q1 2017.
  • Rock Springs Capital Management opened 9 new positions and closed 2 in Q1 2017.
  • Rock Springs Capital Management's portfolio value rose 16% quarter-over-quarter to $1.73B.

Based on Rock Springs Capital Management's 13F filing for Q1 2017, filed 15 May 2017.